Leerink Partnrs Has Pessimistic View of REGN Q1 Earnings
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $7.07 per share for the quarter, […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $7.07 per share for the quarter, […]
